Total Payments
$17,849
2024 Payments
$6,401
Companies
7
Transactions
24
Medicare Patients
638
Medicare Billing
$219,162
Payment Breakdown by Category
Consulting$13,288 (74.4%)
Other$3,200 (17.9%)
Travel$831.69 (4.7%)
Food & Beverage$530.29 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $13,288 | 7 | 74.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,200 | 2 | 17.9% |
| Travel and Lodging | $831.69 | 6 | 4.7% |
| Food and Beverage | $530.29 | 9 | 3.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $9,201 | 15 | $0 (2024) |
| Lilly USA, LLC | $3,413 | 3 | $0 (2021) |
| Life Technologies Corporation | $2,800 | 2 | $0 (2022) |
| Rigel Pharmaceuticals, Inc. | $1,800 | 1 | $0 (2021) |
| Eli Lilly and Company | $525.00 | 1 | $0 (2020) |
| Abbott Laboratories | $75.28 | 1 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $35.46 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,401 | 14 | Gilead Sciences, Inc. ($6,401) |
| 2022 | $1,400 | 1 | Life Technologies Corporation ($1,400) |
| 2021 | $9,488 | 7 | Lilly USA, LLC ($3,413) |
| 2020 | $525.00 | 1 | Eli Lilly and Company ($525.00) |
| 2017 | $35.46 | 1 | AstraZeneca Pharmaceuticals LP ($35.46) |
All Payment Transactions
24 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $70.76 | General |
| Category: COVID-19 | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $47.94 | General |
| Category: COVID-19 | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $36.68 | General |
| Category: COVID-19 | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $27.29 | General |
| Category: COVID-19 | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $25.61 | General |
| Category: COVID-19 | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $21.32 | General |
| Category: COVID-19 | ||||||
| 12/06/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Consulting Fee | Cash or cash equivalent | $5,150.00 | General |
| Category: COVID-19 | ||||||
| 11/15/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $73.13 | General |
| Category: COVID-19 | ||||||
| 11/15/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $59.99 | General |
| Category: COVID-19 | ||||||
| 11/15/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $59.99 | General |
| Category: COVID-19 | ||||||
| 11/15/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $59.99 | General |
| Category: COVID-19 | ||||||
| 11/14/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $336.59 | General |
| Category: COVID-19 | ||||||
| 11/14/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $281.95 | General |
| Category: COVID-19 | ||||||
| 11/14/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: COVID-19 | ||||||
| 10/26/2022 | Life Technologies Corporation | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 09/21/2021 | Lilly USA, LLC | — | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| 09/14/2021 | Life Technologies Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| 06/24/2021 | Lilly USA, LLC | — | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| 05/26/2021 | Gilead Sciences, Inc. | Veklury (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: COVID-19 | ||||||
| 05/14/2021 | Abbott Laboratories | HeartMate 3 Left Ventricular Assist Device (Device) | Food and Beverage | In-kind items and services | $75.28 | General |
| Category: Heart Failure | ||||||
| 04/27/2021 | Lilly USA, LLC | — | Consulting Fee | Cash or cash equivalent | $2,362.50 | General |
| 02/08/2021 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Hematology | ||||||
| 05/21/2020 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| 05/22/2017 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $35.46 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 105 | 166 | $96,867 | $21,831 |
| 2022 | 4 | 166 | 351 | $207,945 | $53,639 |
| 2021 | 5 | 179 | 403 | $239,294 | $63,706 |
| 2020 | 4 | 188 | 483 | $299,963 | $79,986 |
Total Patients
638
Total Services
1,403
Medicare Billing
$219,162
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 56 | 97 | $71,113 | $15,574 | 21.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 11 | 19 | $8,884 | $2,161 | 24.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 18 | 28 | $9,008 | $2,056 | 22.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 22 | $7,862 | $2,040 | 26.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 86 | 236 | $167,336 | $43,182 | 25.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 52 | 77 | $25,405 | $6,727 | 26.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 17 | 27 | $8,666 | $2,005 | 23.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 11 | 11 | $6,538 | $1,725 | 26.4% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 92 | 276 | $195,332 | $51,886 | 26.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 45 | 72 | $24,003 | $6,429 | 26.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 15 | $9,698 | $2,597 | 26.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 24 | $7,232 | $1,912 | 26.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 12 | 16 | $3,029 | $881.85 | 29.1% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 99 | 347 | $248,799 | $66,592 | 26.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 51 | 95 | $32,205 | $8,669 | 26.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 20 | 21 | $13,839 | $3,551 | 25.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 18 | 20 | $5,120 | $1,174 | 22.9% |
About Dr. Peter Chen, M.D
Dr. Peter Chen, M.D is a Pulmonary Disease healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1225100183.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Chen, M.D has received a total of $17,849 in payments from pharmaceutical and medical device companies, with $6,401 received in 2024. These payments were reported across 24 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($13,288).
As a Medicare-enrolled provider, Chen has provided services to 638 Medicare beneficiaries, totaling 1,403 services with total Medicare billing of $219,162. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Seattle, WA
- Active Since 11/15/2006
- Last Updated 09/03/2015
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1225100183
Products in Payments
- Veklury (Drug) $9,201
- Tavalisse (Drug) $1,800
- HeartMate 3 Left Ventricular Assist Device (Device) $75.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Seattle
Ganesh Raghu, Md, MD
Pulmonary Disease — Payments: $346,087
Pulmonary Disease $346,087
Jeffrey Cary, Md, MD
Pulmonary Disease — Payments: $170,288
Pulmonary Disease $170,288
Dr. Vinay Gupta, Md, MD
Pulmonary Disease — Payments: $166,440
Pulmonary Disease $166,440
Christopher Goss
Pulmonary Disease — Payments: $62,687
Pulmonary Disease $62,687
Dr. Amy Dickey, Md, MD
Pulmonary Disease — Payments: $48,254
Pulmonary Disease $48,254
Reena Mehra, Md, MD
Pulmonary Disease — Payments: $37,758
Pulmonary Disease $37,758